November 18, 2005 -- An FDA advisory panel ruled that it did not have enough information to prove that Tamiflu caused deaths and neuropsychological events in Japanese children; Reliant Pharma pulled its $300 million IPO; Vernalis PLC will pay up to $64.5 million to acquire Cita NeuroPharmaceuticals of Canada; Inex Pharma will spin off its Targeted Immunotherapy business into a new company; and Gilead released positive interim data from a test of its combination AIDS drug, Truvada. With a two-point gain, the Centient Biotech 200™ scored a new all-time high, closing at 3988.47, an increase of .05%. More details...
